Loading stock data…
BSX
$48.96+0.26 (+0.53%)
Market ClosedLast close Jun 9
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Boston Scientific Corporation in the Healthcare sector is trading at $48.96. Wall Street consensus targets $78.17 (30 analysts), implying a +59.7% move over the next 12 months. The stock is currently near its 52-week low of $47.17, remaining 41.2% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. Risk note: RSI 20 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +59.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 20) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$48.96
Potential Downside
0%
Whystock Fair Value$48.96
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus30 analysts
Mean target$78.17+59.7%
Range$55.00 – $106.00
Fundamentals
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and tre...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
13.78%
Volume
Today's trading volume
16.23M
Recent News
Is Boston Scientific (BSX) One of the Best Healthcare Stocks to Buy With the Highest Upside Potential?
Boston Scientific Corporation (NYSE:BSX) is one of the best healthcare stocks to buy with highest upside potential. TD Cowen cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $80 on May 29, maintaining a Buy rating on the shares and stating that the firm updated its model to account for the latest Watchman […]
Boston Scientific to build Indiana distribution center
The planned logistics site, near a principal manufacturing facility, will handle global distribution of Boston Scientific’s medical devices.
Boston Scientific (BSX) Initiates $2B Accelerated Share Repurchase Agreement
Boston Scientific Corporation (NYSE:BSX) is one of the oversold stocks to buy right now. On May 18, Boston Scientific entered into an accelerated share repurchase/ASR agreement with JPMorgan Chase Bank to buy back $2 billion of its common stock, part of a previously authorized $5 billion program. The company will immediately receive approximately 30.4 million […]
Is Boston Scientific Corporation (BSX) One of the Top Cheap Stocks With Strong Buy Ratings on Wall Street?
Boston Scientific Corporation (NYSE:BSX) is one of top cheap stocks with Strong Buy ratings on Wall Street. Boston Scientific Corporation (NYSE:BSX) received a rating update from Canaccord on June 1. The firm lowered the price target on the stock to $70 from $71, reiterating a Buy rating on the shares. Canaccord stated that it updated […]
How Investors May Respond To Boston Scientific (BSX) Strong Q1 Beat But Cut Guidance On Watchman Growth
In late April 2026, Boston Scientific reported quarterly revenue of US$5.20 billion, up 11.6% year on year and ahead of expectations, but cut near-term and full-year guidance amid intensifying cardiac market competition and slowing growth in its Watchman stroke-prevention device. This combination of strong recent performance and a more cautious outlook, reinforced by downgrades from firms like Wolfe Research, has sharpened investor focus on how resilient Boston Scientific’s growth drivers...